Pharma Insights 2026: FDA 505(b)(2) Approvals, Biotech Lawsuits, and Critical IP Decisions
Welcome back to our weekly industry roundup! May 2026 has been an action-packed month for the pharmaceutical and intellectual property sectors. From game-changing FDA approvals that ease patient pill burdens to high-stakes patent battles in Delaware, we are breaking down the biggest headlines you need to know.
1. May 2026 FDA 505(b)(2) Approvals: Innovation
The FDA’s 505(b)(2) regulatory pathway bridges the gap between brand-new drug development and traditional generics. This month, we saw five standout drug approvals and tentative approvals that promise to reshape market dynamics, enhance patient compliance, and drive down healthcare costs.
Here is a quick breakdown of the latest regulatory milestones:
| Drug Name & Sponsor | Active Ingredient(s) | Status | Key Clinical & Commercial Takeaway |
JAKAFI XR
(Incyte Corp) | Ruxolitinib Phosphate | Approved | A new, proprietary extended-release formulation. Its once-daily (QD) dosing replaces a twice-daily regimen, reducing pill fatigue and helping Incyte defend its multibillion-dollar market share against generic competition. |
EVDI
(Apotex) | Trabectedin | Approved | References the blockbuster oncology drug Yondelis. As the only other generic alternative available today, it introduces vital cost-competition into a niche $150M to $200M annual US market. |
DOLUTEGRAVIR, LAMIVUDINE & TDF
(Lachman Consultant Services) | Dolutegravir / Lamivudine / Tenofovir Disoproxil Fumarate | Tentative Approval | Optimises global first-line HIV-1 protocols into an affordable, single-pill daily regimen. Final market launch is blocked until core patents expire (the latest being December 8, 2029). |
TRIMBOW
(Chiesi USA) | Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate | Approved | A fixed-dose single-inhaler triple therapy (SITT) for adult asthma. Its extrafine formulation targets small airway disease, eliminating the need for multiple inhalers. |
DIFFERIN EPIDUO ACNE GEL
(Galderma Laboratories) | Adapalene 0.1% / Benzoyl Peroxide 2.5% | Approved (Rx-to-OTC Switch) | A major strategic shift launching in summer 2026. It is the first stable, fixed-dose OTC gel combining a third-generation retinoid with an antimicrobial agent, eliminating the need for expensive dermatology visits. |
2. Global Legal Updates: Compliance Risks and Unproven Science
Munich Court Orders Arrest Warrant for Polytech General Manager
This is the kind of decision that should make every corporate compliance department sit up and take notice. The Munich Regional Court has ordered an arrest for disobedience against court orders targeting the managing director of Polytech Health & Aesthetics GmbH (or alternatively, their successor).
The Takeaway: Anyone who violates a court injunction "particularly grossly" faces not just heavy corporate fines, but personal imprisonment as a managing director.
Experimental Spinal Cord Treatment Triggers Frenzy in Brazil
An unproven treatment using polylaminin (a placenta-derived protein aiming to promote nerve regeneration) has sparked international hype, drawing patients to a small-town laboratory in Brazil. Despite a complete lack of safety verification via clinical trials, the frenzy has mobilised government pressure for expedited approval and triggered dozens of lawsuits from families desperate to gain access to the drug.
3. Intellectual Property Spotlight: UCB Defeats Cipla in Nayzilam Patent Battle
In a definitive ruling, the U.S. District Court for the District of Delaware upheld the validity of the patents protecting UCB’s nasal spray, Nayzilam. The Judge concluded that the generic challenger, Cipla Limited, failed to prove that UCB's patent claims were anticipated or obvious.
The Backstory
Nayzilam (midazolam) is an emergency intranasal rescue treatment for acute repetitive seizures (ARS). Formulating midazolam for nasal delivery is notoriously difficult because the nasal cavity can only hold 100–200 µL of liquid, requiring an ultra-concentrated solution. UCB successfully solved this by using a specific excipient: mPEG-350.
Why Cipla's Arguments Failed
The "Anticipation" Defeat: Cipla argued that a prior art reference mentioning "polyethylene glycol" (PEG) anticipated the formulation. The Court flatly rejected this, noting that PEG and mPEG are entirely distinct chemical entities with different structures, synthesis methods, and separate pharmaceutical compendia listings.
The "Obviousness" Defeat: Cipla claimed a person of ordinary skill in the art (POSA) would naturally think to use mPEG-350. However, the Court pointed out that prior to 2007, mPEG had never been used in a nasal drug. The FDA even classified it as a "novel excipient" for nasal routes, making Cipla's argument pure hindsight.
The Smoking Gun
In a striking revelation during the trial, it was noted that from 2018 onward, Cipla spent three years attempting to develop an alternative intranasal midazolam formulation without mPEG. After evaluating dozens of variations, they ultimately failed—proving they had to copy UCB's mPEG-dependent composition to get an effective product.
----------------XX----------------XX---------------------
Contents
Recent 505 (b) (2) filings
General information
Munich Court orders arrest for Polytech general manager
Little-tested spinal cord treatment triggers hope, hype and lawsuits in Brazil
Intellectual Property
UCB, Inc. et al. v. Cipla Limited et al
Recent 505 (b) (2) filings
We follow 505 (b) (2) filings.
Generally, 505(b)(2) NDAs relate to changes compared to previously approved drugs, such as indication, active ingredient, fixed-combination, dosage form, route of administration, dosing regimen, strength, and formulation (not approvable under section 505(j)). More details 505 (b) (2) FDA approvals can be found here.
The details of May 2026, 505 (b) (2) filings are as follows:
General information
Munich Court orders arrest for Polytech general manager
It is the kind of decision that makes compliance departments sit up and take notice. Anyone who violates a court injunction “particularly grossly” risks not only a fine but also personal imprisonment as a managing director. The Munich Regional Court has ordered an arrest for disobedience against court orders against the managing director of Polytech Health & Aesthetics GmbH, alternatively against his successor
Little-tested spinal cord treatment triggers hope, hype and lawsuits in Brazil
An experimental treatment for spinal cord injuries has ignited a frenzy in Brazil, drawing patients from as far off as Mexico to a small-town laboratory, mobilizing the government to expedite approval and turning a scientist into a national celebrity – all before its safety has been proven in a clinical trial.
The buzz around polylaminin, a placenta-derived protein aimed at promoting nerve regeneration, has lured interest from thousands of potential patients worldwide, with dozens hiring lawyers to gain access to the drug.
Intellectual Property
UCB, Inc. et al. v. Cipla Limited et al
Executive Summary
In UCB, Inc. et al. v. Cipla Limited et al., the U.S. District Court for the District of Delaware ruled that defendants Cipla Limited and Cipla USA Inc. ("Cipla") failed to prove that the asserted patent claims covering UCB’s nasal spray NAYZILAM are invalid. Following a bench trial, the U.S. District Judge concluded that the challenged claims are neither anticipated nor obvious.
Technical and Operational Background
The litigation concerns generic competition for Nayzilam, an FDA-approved intranasal rescue treatment for acute repetitive seizures (ARS) in epilepsy patients. ARS involves unpredictable seizure clusters that carry high risks of injury, hospitalisation, or life-threatening status epilepticus. Prompt treatment is vital. Prior to Nayzilam's approval, the only available at-home rescue option was DIASTAT, a rectal gel that caregivers and patients frequently found embarrassing and socially difficult to administer.
The active pharmaceutical ingredient in Nayzilam is midazolam. Formulating midazolam for nasal delivery poses significant challenges: the nasal cavity can hold only 100–200 µL of liquid, requiring a highly concentrated solution. Additionally, midazolam base has poor water solubility. The inventor discovered that utilising methoxypolyethylene glycol (mPEG), specifically mPEG-350, enabled high drug solubilisation while reducing viscosity and mucosal irritation, resulting in an optimised spray pattern.
The Dispute and Asserted Claims
UCB alleged that Cipla’s ANDA to market a generic version of Nayzilam infringed claim 13 of U.S. Patent No. 8,217,033 and claim 10 of U.S. Patent No. 8,809,322. The shared patents have a priority date of January 19, 2007.
- The '033 Patent (Claim 13): Protects a liquid intranasal pharmaceutical composition combining midazolam, propylene glycol, water, polyethylene glycol 400 (PEG-400), and mPEG-350.
- The '322 Patent (Claim 10): Protects a liquid intranasal pharmaceutical composition comprising a therapeutically effective amount of midazolam and an mPEG of a specific chemical formula where the repeating units (n) range from 2 to 12.
Cipla stipulated to infringement but argued that the claims were invalid due to anticipation and obviousness.
Legal Analyses
1. Anticipation Under § 102
Cipla contended that the claims were anticipated by
Wermeling '359, a prior art publication describing intranasal benzodiazepine compositions. Cipla argued Wermeling '359's text encompassed mPEG-350 under its general references to "polyethylene glycol".
The Court rejected this, finding that Wermeling '359 did not disclose mPEG either expressly or inherently. The Court emphasised that PEG and mPEG are distinct chemical entities with different chemical structures, separate synthesis methods, and unique CAS Registry Numbers. Standard pharmaceutical compendia explicitly separate the two. Because a person of ordinary skill in the art (POSA) would not read "PEG" to include mPEG, Cipla failed to show that a single prior art reference described every limitation of the claims.
2. Obviousness Under § 103
Cipla next argued that the claims were obvious based on combining Wermeling '359 with Carbowax, a marketing brochure detailing Dow Chemical's PEG and mPEG lines. Cipla claimed a POSA would have substituted propylene glycol with mPEG-350 and water to reduce viscosity or improve tolerability.
The Court found no motivation to combine or a reasonable expectation of success, rendering Cipla’s arguments a reflection of pure hindsight. Key findings included:
- No Nasal Prior Art: Before 2007, mPEG had never been used, marketed, or suggested for any intranasal formulation. Its single FDA-approved pharmaceutical application was in a topical gel.
- Unknown Properties: A POSA would have no baseline data to predict how mPEG would affect midazolam solubility, nasal ciliary safety, mucosal permeability, or device sprayability.
- Regulatory Inapplicability: The FDA considered mPEG a "novel excipient" for the nasal route and explicitly ruled its topical safety history irrelevant, requiring separate toxicity studies.
- Lack of Motivation: Wermeling '359 gave no indication that its formulation's viscosity or tolerability required modification.
3. Objective Indicia of Non-Obviousness
The Court evaluated secondary considerations, noting a strong long-felt need for a socially acceptable, non-invasive ARS rescue drug. Notably, from 2018 onward, Cipla spent three years developing an intranasal midazolam alternative without mPEG, evaluating dozens of formulations. Cipla ultimately failed to develop an effective formulation via the generic pathway without copying UCB's mPEG-dependent composition.
Conclusion
Definitely resolving the challenge, the Judge ruled that Cipla failed to provide clear and convincing evidence of invalidity. The Court upheld the validity of the patents-in-suit and ordered the parties to submit a proposed final judgment
